Janus Henderson Global Life Sciences D’s management team is just average, but a solid investment process still helps this strategy retain its Morningstar Quantitative Rating of Bronze. The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.
- NAV / 1-Day Return 67.16 / 0.70 %
- Total Assets 4.7 Bil
Adj. Expense Ratio
- Expense Ratio 0.800%
- Distribution Fee Level Below Average
- Share Class Type No Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Limited
- TTM Yield 0.25%
- Turnover 21%
Morningstar’s Analysis JNGLX
Will JNGLX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.